Xenon Pharmaceuticals annual revenue
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
Xenon Pharmaceuticals Revenue Growth & History (XENE)
Xenon Pharmaceuticals reported $7.5M in revenue for fiscal 2025.
View full Xenon Pharmaceuticals company overviewXenon Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.5M | $7.5M | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$9.4M | −100.00% |
| 2022 | 2022-12-31 | $9.4M | −$9.0M | −48.83% |
| 2021 | 2021-12-31 | $18.4M | −$13.7M | −42.68% |
| 2020 | 2020-12-31 | $32.2M | $25.3M | +371.02% |
| 2019 | 2019-12-31 | $6.8M | — | — |
| 2017 | 2017-12-31 | $311,000 | −$1.5M | −82.75% |
| 2016 | 2016-12-31 | $1.8M | −$13.8M | −88.43% |
| 2015 | 2015-12-31 | $15.6M | −$12.8M | −45.09% |
| 2014 | 2014-12-31 | $28.4M | $1.0M | +3.71% |
| 2013 | 2013-12-31 | $27.4M | $13.0M | +91.19% |
| 2012 | 2012-12-31 | $14.3M | — | — |
Xenon Pharmaceuticals quarterly revenue
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | −$7.5M | −100.00% |
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q1 2025 | 2025-03-31 | $7.5M | $7.5M | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | — | — |
| Q2 2024 | 2024-06-30 | $0 | — | — |
| Q1 2024 | 2024-03-31 | $0 | — | — |
| Q4 2022 | 2022-12-31 | $0 | −$3.7M | −100.00% |
| Q3 2022 | 2022-09-30 | $132,000 | −$8.0M | −98.38% |
| Q2 2022 | 2022-06-30 | $536,000 | −$1.7M | −75.83% |
| Q1 2022 | 2022-03-31 | $8.8M | $4.4M | +101.15% |
| Q4 2021 | 2021-12-31 | $3.7M | −$1.4M | −27.44% |
| Q3 2021 | 2021-09-30 | $8.1M | $1.6M | +23.95% |
| Q2 2021 | 2021-06-30 | $2.2M | −$11.2M | −83.43% |
| Q1 2021 | 2021-03-31 | $4.4M | −$2.7M | −38.43% |
| Q4 2020 | 2020-12-31 | $5.2M | — | — |
| Q3 2020 | 2020-09-30 | $6.6M | $3.1M | +87.26% |
| Q2 2020 | 2020-06-30 | $13.4M | — | — |
| Q1 2020 | 2020-03-31 | $7.1M | — | — |
| Q3 2019 | 2019-09-30 | $3.5M | — | — |
| Q4 2017 | 2017-12-31 | $16,000 | −$360,000 | −95.74% |
| Q3 2017 | 2017-09-30 | $264,000 | −$149,000 | −36.08% |
| Q2 2017 | 2017-06-30 | $15,000 | −$398,000 | −96.37% |
| Q1 2017 | 2017-03-31 | $16,000 | −$585,000 | −97.34% |
| Q4 2016 | 2016-12-31 | $376,000 | −$2.9M | −88.35% |
| Q3 2016 | 2016-09-30 | $413,000 | −$3.9M | −90.38% |
| Q2 2016 | 2016-06-30 | $413,000 | −$3.6M | −89.79% |
| Q1 2016 | 2016-03-31 | $601,000 | −$3.4M | −85.01% |
| Q4 2015 | 2015-12-31 | $3.2M | −$1.7M | −33.85% |
| Q3 2015 | 2015-09-30 | $4.3M | −$8.9M | −67.45% |
| Q2 2015 | 2015-06-30 | $4.0M | −$1.3M | −23.63% |
| Q1 2015 | 2015-03-31 | $4.0M | −$991,000 | −19.82% |
| Q4 2014 | 2014-12-31 | $4.9M | −$705,000 | −12.63% |
| Q3 2014 | 2014-09-30 | $13.2M | $2.4M | +22.29% |
| Q2 2014 | 2014-06-30 | $5.3M | −$302,000 | −5.39% |
| Q1 2014 | 2014-03-31 | $5.0M | −$384,000 | −7.13% |
| Q4 2013 | 2013-12-31 | $5.6M | — | — |
| Q3 2013 | 2013-09-30 | $10.8M | — | — |
| Q2 2013 | 2013-06-30 | $5.6M | — | — |
| Q1 2013 | 2013-03-31 | $5.4M | — | — |
Xenon Pharmaceuticals revenue growth trends
Over the last five reported fiscal years, revenue declined from $32.2M to $7.5M, a compound annual decline of 25.26%. Xenon Pharmaceuticals's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Xenon Pharmaceuticals source filings ↗Community posts
Xenon files its seizure-drug application while pausing new psychiatry enrollment
Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation t ...
